Citations 1
NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022
Wierda, William G. , Brown, Jennifer R. , Bilgrami, S, Bociek, Greg, Brander, Danielle M. , Chanan‐Khan, Asher , Davis, Randall S. , Eradat, Herbert, Fletcher, Christopher D.�M. , Gaballa, Sameh , Hamid, Muhammad Saad , Hernandez‐Ilizaliturri, Francisco J. , Hill, Brian T. , Kaesberg, Paul, Kaplan, Lawrence D. , Ma, Shuo , Mato, Anthony, Mosse, Claudio A. , Stephens, Deborah M. , Ujjani, Chaitra S. , Wagner‐Johnston, Nina D. , Woyach, Jennifer A. , Ye, J Christine, Dwyer, Mary A., Sundar, Hema, Chanan-Khan, Asher A., Stephens, Deborah M , Ma, Shuo , Wierda, William G. , Abramson, Jeremy S. , Awan, Farrukh T. , Coutré, Steven , Ghobadi, Armin , Kamdar, Manali , Khan, Nadia , Kipps, Thomas J. , Schuster, Stephen J. , Siddiqi, Tanya
Journal of the National Comprehensive Cancer Network | June 17, 2022 | Volume: 20 | Issue: 6 | Pages: 622-634
The treatment landscape of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has significantly evolved in recent years. Targeted therapy with Bruton’s tyrosine kinase (BTK) inhibitors and BCL-2 inhibitors has emerged as an effective chemotherapy-free option for patients with previously untreated or relapsed/refractory CLL/SLL. Undetectable minimal residual disease after the end of treatment is emerging as an important predictor of progression-free and overall survival for patients treated with fixed-duration BCL-2 inhibitor-based treatment. These NCCN Guidelines Insights discuss the updates to the NCCN Guidelines for CLL/SLL specific to the use of chemotherapy-free treatment options for patients with treatment-naïve and relapsed/refractory disease.